Automated Microbiology Market (2026 - 2033)

Automated Microbiology Market Summary

The global automated microbiology market size was valued at USD 5.3 billion in 2025 and is projected to grow from USD 5.6 billion in 2026 to USD 9.5 billion by 2033, at a CAGR of 7.7% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 41.0% in 2025. The market growth is driven by the rising burden of antimicrobial resistance and sepsis, which requires faster identification and susceptibility testing, shortages of trained laboratory staff that push laboratories toward automation, and growing quality control testing in biopharmaceutical and food production.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

To learn more about this report, Download Free Sample Report

Market Dynamics

The market is growing steadily as clinical and industrial laboratories replace manual culture, identification, and susceptibility testing with automated systems that deliver faster and more consistent results. The burden of infections that require culture-based diagnosis remains high. According to the Global Research on Antimicrobial Resistance (GRAM) study published in The Lancet in September 2024, antimicrobial resistance directly caused 1.14 million deaths in 2021 and was associated with 4.71 million deaths, while the WHO estimates 48.9 million sepsis cases and 11 million sepsis-related deaths each year. Automated blood culture, MALDI-TOF identification, and rapid AST systems shorten the time to targeted therapy, which supports their adoption in hospital laboratories.

Industry Concentration & Characteristics

The degree of innovation in the automated microbiology industry is high, driven by MALDI-TOF identification, rapid AST, total laboratory automation, and AI-based image analysis. For instance, in April 2024, Q-linea received U.S. FDA 510(k) clearance for its ASTar System, which provides rapid antimicrobial susceptibility results directly from positive blood cultures in about six hours.

The automated microbiology industry is witnessing a moderate to high level of M&A activity, as large companies reshape their diagnostics portfolios. For instance, in February 2026, BD completed the combination of its Biosciences & Diagnostic Solutions business, which includes BD BACTEC, Phoenix, and Kiestra, with Waters Corporation, valuing the business at USD 18.8 billion. In August 2026, Thermo Fisher Scientific completed the sale of its microbiology business, including Oxoid and Remel, which generated USD 645 million in revenue in 2025, to private equity firm Astorg for about USD 1.1 billion.

To learn more about this report, Download Free Sample Report

“The successful combination of our Biosciences & Diagnostic Solutions business with Waters marks the final milestone of our BD 2025 strategy, positioning BD for its next chapter as a focused, pure-play MedTech company built for the next era of healthcare.”

- Tom Polen, Chairman, Chief Executive Officer and President, BD

Regulations have a high impact on the automated microbiology industry, as automated systems and their reagents are regulated as in vitro diagnostic devices and must meet performance and quality requirements. In May 2024, the WHO updated its Bacterial Priority Pathogens List, covering 15 families of antibiotic-resistant bacteria, which guides surveillance and testing priorities. In the U.S., a federal court vacated the FDA's Laboratory Developed Tests rule in March 2025, keeping laboratory-developed microbiology assays under CLIA oversight.

The automated microbiology industry is witnessing product expansion as leading companies renew their automated ID/AST platforms. For instance, in March 2025, bioMérieux received U.S. FDA 510(k) clearance for VITEK COMPACT PRO, a next-generation automated identification and antibiotic susceptibility testing system designed for both clinical and industrial laboratories.

“VITEK® COMPACT PRO delivers fast, accurate and reproducible results comparable to VITEK® 2 and VITEK® 2 COMPACT systems.”

- Céline Roger-Dalbert, Executive Vice President, Research and Development, bioMérieux

The automated microbiology industry is witnessing regional expansion as companies add local manufacturing and service capacity. For instance, in September 2025, Copan announced more than USD 7 million in new U.S. manufacturing investment in California and Puerto Rico to expand production capacity and domestic sourcing.

“With more than three decades of United States presence, we remain committed to fostering economic growth by strengthening local manufacturing, increasing access to advanced technologies, and creating new employment opportunities in our communities.”

- Fabrizio Mazzocchi, CEO, COPAN Diagnostics Inc.

Analyst Perspective

The automated microbiology market is expected to witness steady growth, supported by rising antimicrobial resistance and sepsis burden, shortages of laboratory staff, and growing quality control testing in biopharmaceutical and food production. Reagents and kits remain the largest revenue source because of recurring consumption on installed systems, while lab automation instruments and software are expected to grow faster. Fully automated systems continue to gain share as laboratories invest in total laboratory automation, MALDI-TOF identification, and rapid AST. Market participants are focusing on new rapid testing systems, AI-based image analysis, acquisitions, and expansion of manufacturing and service networks.

Product Insights

The reagents & kits segment accounted for the largest revenue share of 61.8% in 2025, as each installed system generates recurring demand for ID and AST panels, blood culture bottles, culture media, and other consumables. Within this segment, assay kits & panels held the largest share of 51.7% in 2025. For instance, in July 2026, bioMérieux reported 4.3% organic growth in clinical microbiology in the first half of 2026, led by BACT/ALERT blood culture bottles.

The instruments segment is expected to grow at a CAGR of 8.1% over the forecast period, supported by investments in lab automation. Within instruments, automated sample preparation systems are projected to grow the fastest at a CAGR of 8.7%. For instance, in November 2025, the Los Angeles County Board of Supervisors approved the purchase of a Copan WASPLab total lab automation system with PhenoMATRIX for Harbor-UCLA Medical Center for about USD 2.6 million, allowing the laboratory to process up to 416 additional specimens per day without extra staff. The software segment is expected to grow at the fastest CAGR of 8.3%; in January 2024, bioMérieux acquired LUMED, a developer of software that supports antimicrobial stewardship in hospitals.

Application Insights

The clinical diagnostics segment accounted for the largest revenue share of 54.0% in 2025, driven by high volumes of blood, urine, and respiratory cultures in hospital laboratories. Updated guidance is reinforcing the role of culture-based testing; in March 2026, the Surviving Sepsis Campaign international guidelines recommended obtaining blood cultures as soon as possible and ideally before antimicrobial therapy is started.

The biopharmaceutical production segment is projected to grow at the fastest CAGR of 8.3% during 2026-2033, supported by growing quality control testing for sterility, bioburden, and environmental monitoring. For instance, bioMérieux reported 8.8% organic growth in its industrial applications business in 2025, with pharmaceutical quality control growing about 14%. The food & beverage testing segment is expected to grow at a CAGR of 7.9%; in January 2025, bioMérieux completed the acquisition of Brazil-based Neoprospecta, which provides microbiome analytics for food and pharmaceutical quality control.

End Use Insights

The hospitals & diagnostic laboratories segment accounted for the largest revenue share of 49.0% in 2025, as these laboratories perform most clinical culture, identification, and susceptibility testing and are the main buyers of blood culture, ID/AST, and lab automation systems.

The pharmaceutical & biotechnology companies segment is expected to grow at the fastest CAGR of 8.2% over the forecast period, driven by expanding biologics manufacturing and stricter microbial quality control requirements. The academic & research institutes segment is expected to grow at a CAGR of 7.6%.

Automation Type Insights

The fully automated segment accounted for the largest revenue share of 64.4% in 2025 and is expected to grow at the fastest CAGR of 8.0% over the forecast period, as laboratories adopt continuous-monitoring blood culture systems, fully automated ID/AST systems, and total laboratory automation to manage rising specimen volumes with fewer staff.

To learn more about this report, Download Free Sample Report

The semi-automated segment is expected to grow at a CAGR of 7.1% during 2026-2033, as small and mid-sized laboratories, particularly in emerging markets, adopt semi-automated ID/AST systems and plate readers that require lower capital investment.

Regional Insights

North America dominated the automated microbiology market, accounting for the largest revenue share of 41.0% in 2025, supported by a large installed base of automated microbiology systems, high testing volumes, and the presence of leading companies such as bioMérieux, Waters (BD), Danaher, and Bruker.

To learn more about this report, Download Free Sample Report

U.S. Automated Microbiology Market Trends

The automated microbiology market in the U.S. is expected to grow over the forecast period, supported by FDA clearances of new rapid testing systems. For instance, in April 2026, Q-linea received FDA clearance for its expanded ASTar Gram-negative blood culture panel, covering 215 bug-drug combinations with results in about six hours from a positive blood culture.

“Our FDA-cleared panel now closely matches what ASTar already provides to patients in Europe and other markets under CE-IVDR clearance. We look forward to providing patients in the US with the full power of the ASTar platform to improve outcomes and reduce costs for healthcare systems.”

- Stuart Gander, CEO, Q-linea

Europe Automated Microbiology Market Trends

The automated microbiology market in Europe is anticipated to grow significantly over the forecast period, supported by a strong base of microbiology laboratories and suppliers. The EU In Vitro Diagnostic Regulation (IVDR) is shaping product renewals; in July 2024, the EU extended the IVDR transition periods for legacy devices to 2027-2029, depending on device class, giving manufacturers more time to certify AST panels, culture media, and identification systems.

The UK automated microbiology market is expected to grow over the forecast period, supported by national efforts to tackle antimicrobial resistance. In May 2024, the UK government published its five-year national action plan, "Confronting antimicrobial resistance 2024 to 2029", noting that nearly 8,000 people in the UK die each year from drug-resistant infections, which is anticipated to propel demand for faster microbiology testing.

The automated microbiology market in Germany is anticipated to grow significantly over the forecast period, supported by investments in hospital laboratory automation. For instance, in May 2024, Universitätsmedizin Rostock opened an automated laboratory line in its new emergency center, shared by clinical chemistry, transfusion medicine, and the Institute for Medical Microbiology, Virology and Hygiene, with equipment worth EUR 4.4 million.

Asia Pacific Automated Microbiology Market Trends

The automated microbiology market in Asia Pacific is expected to grow at the fastest CAGR of 8.7% during the forecast period, supported by investments in hospital laboratories and rising AMR surveillance. For instance, in September 2024, NSW Health Pathology opened a new microbiology laboratory with a robotic track automation system at Liverpool Hospital in Sydney, where microbiology sample volumes rose from about 203,000 in 2018/19 to 283,000 in 2023/24. In India, in August 2025, KIMS in Bhubaneswar installed the first MALDI-TOF microbial identification system in Odisha.

China automated microbiology market is expected to grow over the forecast period, supported by large testing volumes and a high burden of resistant infections. According to the China Antimicrobial Surveillance Network (CHINET), its 2025 surveillance covered more than 516,000 clinical isolates from 80 hospitals, with carbapenem resistance of about 72% in A. baumannii, which is anticipated to propel demand for automated identification and susceptibility testing. Volume-based procurement of diagnostics may slow price growth in the near term.

The automated microbiology market in Japan is expected to grow steadily, supported by the economic value of faster diagnosis. A health-economic analysis published by bioMérieux and the Office of Health Economics in April 2026 found that fast identification and susceptibility testing for bloodstream infections could reduce sepsis cases by more than 20% across G7 countries, with the highest per-patient savings, about EUR 3,800, in Japan.

Latin America Automated Microbiology Market Trends

The automated microbiology market in Latin America is expected to grow steadily over the forecast period, supported by the first investments in full microbiology automation in the region. For instance, in February 2025, Hospital Angeles Pedregal in Mexico City installed the first Copan WASPLab microbiology automation line in Latin America, covering specimen processing, smart incubation, and digital imaging.

MEA Automated Microbiology Market Trends

The automated microbiology market in MEA is growing steadily, supported by private hospital investment in advanced laboratory technologies. For instance, in February 2025, Saudi German Health and BD signed a memorandum of understanding in Jeddah to bring BD BACTEC blood culture, Phoenix ID/AST, EpiCenter data management, and MALDI-TOF systems to the group's laboratories, expected to benefit about 2 million patients each year.

“Technologies like MALDI-TOF have demonstrated their effectiveness in enhancing diagnostic outcomes in other regions, and we believe this collaboration will yield similar results in the Kingdom of Saudi Arabia.”

- Philippe Villard, Senior Director of Commercial Operations, EMEA, BD

Key Automated Microbiology Company Insights

The market is moderately consolidated, with a few global leaders and a number of specialized and regional suppliers. Leading players include bioMerieux SA, Waters Corporation (BD Diagnostic Solutions), Danaher Corporation (Beckman Coulter), Bruker Corporation, Merck KGaA, Copan Group, Autobio Diagnostics Co., Ltd., Charles River Laboratories, Rapid Micro Biosystems, Inc., and Q-linea AB. These companies focus on new automated ID/AST and rapid testing systems, total laboratory automation, AI-based software, acquisitions, and expansion of manufacturing and service networks.

Key Automated Microbiology Companies

The following key companies have been profiled for this study on the automated microbiology market.

• bioMerieux SA

• Waters Corporation (BD Diagnostic Solutions)

• Danaher Corporation (Beckman Coulter)

• Bruker Corporation

• Merck KGaA

• Copan Group

• Autobio Diagnostics Co., Ltd.

• Charles River Laboratories

• Rapid Micro Biosystems, Inc.

• Q-linea AB

Recent Developments

• In September 2026, Pattern Bioscience received FDA Breakthrough Device Designation for its Urine ID/AST Panel, its second breakthrough designation after the Pneumonia ID/AST Panel. The single-cell platform is designed to deliver identification and susceptibility results directly from patient specimens within hours instead of two to three days.

“Pneumonia and urinary tract infections (UTIs) are the two most common infection types that progress to sepsis, and with this designation, Pattern now has breakthrough-designated programs for both.”

- Carey-Ann Burnham, Ph.D., CEO, Pattern Bioscience

• In June 2026, Bruker showcased its expanding microbiology and infection diagnostics portfolio at ASM Microbe 2026, including FDA-cleared expansions of the MALDI Biotyper CA library to 549 species and the Bruker Arc automated positive blood culture preparation system. The company placed 140 new MALDI Biotyper and IR Biotyper systems in the U.S. in 2025.

“We believe the future of microbiology lies in integrated innovations that can deliver faster, clinically actionable answers for some of the most critical patient conditions, including sepsis.”

- Carla Schneider, Director, Commercial Operations, Microbiology & Infection Diagnostics, Americas, Bruker

• In June 2024, bioMérieux received U.S. FDA 510(k) clearance for the VITEK REVEAL AST System, which delivers antimicrobial susceptibility results for Gram-negative bacteria from positive blood cultures in about 5.5 to 6 hours.

“VITEK® REVEAL™ is fully aligned with bioMérieux's priority to provide innovative diagnostics to support antimicrobial stewardship.”

- Dr. Charles K. Cooper, Executive Vice President, Chief Medical Officer, bioMérieux

Global Automated Microbiology Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global automated microbiology market report based on product, automation type, application, end use, and region:

• Product Outlook (Revenue, USD Billion, 2021 - 2033)

  • Reagents & Kits

    • Assay Kits & Panels

    • Culture Media

    • Stains & Dyes

    • Others

  • Instruments

    • Automated Microbial Identification Systems

    • Automated Blood Culture Systems

    • Automated Antibiotic Susceptibility Testing (AST) Systems

    • Automated Sample Preparation Systems

    • Automated Colony Counters

    • Other Instruments

  • Software

• Automation Type Outlook (Revenue, USD Billion, 2021 - 2033)

  • Fully Automated

  • Semi-Automated

• Application Outlook (Revenue, USD Billion, 2021 - 2033)

  • Clinical Diagnostics

  • Biopharmaceutical Production

  • Food & Beverage Testing

  • Environmental & Water Testing

  • Other Applications

• End Use Outlook (Revenue, USD Billion, 2021 - 2033)

  • Hospitals & Diagnostic Laboratories

  • Pharmaceutical & Biotechnology Companies

  • Other End Use (Environmental & Water Testing Laboratories and Food & Beverage Manufacturers)

  • Academic & Research Institutes

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • Saudi Arabia

    • South Africa

    • UAE

    • Kuwait

Research Methodology

The automated microbiology market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each automated microbiology segment quantified using the revenue-capture definitions in the table below.

Delivered Customizations

This report has been delivered with the following In-depth customizations